Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

January 31, 2030

Study Completion Date

January 31, 2030

Conditions
Brain MetastasesBrain Cancer
Interventions
DRUG

18F-Fluciclovine

Patients will receive 5-mCi dose (+/- 20%) of 18F-Fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-Fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-Fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.

Trial Locations (1)

33176

RECRUITING

Miami Cancer Institute at Baptist Health South Florida, Miami

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Blue Earth Diagnostics

INDUSTRY

lead

Baptist Health South Florida

OTHER

NCT05554302 - Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis | Biotech Hunter | Biotech Hunter